Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Sumitomo_Dainippon_Pharma
|
| gptkbp:CEO |
Nobuhiko Tamura
|
| gptkbp:focusesOn |
respiratory diseases
central nervous system disorders |
| gptkbp:formerName |
Sepracor Inc.
|
| gptkbp:founded |
2009
|
| gptkbp:headquartersLocation |
gptkb:Marlborough,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sunovion Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
Nobuhiko Tamura
|
| gptkbp:notableProduct |
gptkb:Latuda
gptkb:Lunesta Xopenex Brovana |
| gptkbp:numberOfEmployees |
approximately 2,000
|
| gptkbp:operatesIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Sumitomo_Pharma
|
| gptkbp:type |
gptkb:subsidiary
|
| gptkbp:website |
https://www.sunovion.com/
|
| gptkbp:bfsParent |
gptkb:PhRMA
|
| gptkbp:bfsLayer |
6
|